Press Releases

May 27, 2021
Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences
CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 27, 2021-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will
Apr 10, 2021
Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021
- BT7480 to be presented in a “New Drugs on the Horizon” session; on-track to enter the clinic in 2H’21 CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Apr. 10, 2021-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on
Jan 14, 2021
Bicycle Therapeutics Announces Pipeline Progress Update
- BT1718 progressing in Cancer Research UK sponsored Phase IIa clinical trial - Phase I trial of BT5528 currently dosing within predicted therapeutic range; preliminary signs of anti-tumor activity observed, including a partial response - BT8009 pharmacokinetic profile consistent with preclinical